In a recent study by Cohen et al, it was reported that plasma LDL-C is reduced by roughly 1.0 mmol/L by PCSK9 variations, Y142X and C679X; it was also revealed that 88% reduction in CHD prevalence is correlated with PCSK9 variations, Y142X and C679X. Here, PCSK9 is linked to coronary artery disorder.